Efficiency comparison between TP and pemetrexed plus cisplatin for advanced non-small cell lung cancer

ZHOU Xiao-li, XIE Xian-he, LI Shi-yun, DAI Ru-qi
(Nuclear Medicine, People’s Hospital of Hainan Province, Haikou 570311, China)

[Foundation Project]: Hainan Medical University Scientific Research Fund Supported Project of the Journal(0020120012)

[Author]: ZHOU Xiao-Li (1980 - ), Female, Wanning Hainan, M. B. Residency, Tel: 13876688653, E-mail: lianyizzxxill@163.com.

[Correspondence to]: XIE Xian-he (1964-), Male, Liancheng County Fujian Province, Chief Physician, Ph. D., Tel: 13976868269, E-mail: xiexianhe_2006@yahoo.com.cn

Received; 2011-11-03 Revised; 2011-11-08

JHMC, 2012; 18(1), 45-47

View from specialist: It is creative, and of certain scientific and educational value.

[ABSTRACT] Objective: To compare the efficiency of TP and pemetrexed plus cisplatin for advanced non-small cell lung cancer. Methods: Fifty-five patients with advanced NSCLC were randomly divided into pemetrexed plus cisplatin group (26 cases) and TP group (29 cases). The two groups underwent two courses of chemotherapy of pemetrexed plus cisplatin and TP regime respectively. Results: The effective rate of pemetrexed plus cisplatin group was 30.8% while that of TP group was 31.0%, the recent efficiency of the two groups was not significant different (P>0.05). But incidence of white blood cell decrease and hair loss were significantly lower in pemetrexed plus cisplatin group than that in TP Group (P<0.05). There were no significantly difference in incidence of nausea, vomiting, decreased platelets, liver function impairment and anemia (P>0.05). Conclusions: Pemetrexed plus cisplatin shows comparable effects on NSCLC as TP regime, while the side effects were lighter than the latter.

[KEY WORDS] Non-small cell lung cancer; Pemetrexed; Docetaxel; Cisplatin; Chemotherapy